Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.31 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | FCER2 | P06734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19825816 | 1.00 | CPB2 (0.35) | CPB2KDM1AMEN1MITFKMT2A | |
| SCHEMBL26675669 | 0.94 | CPB2 (0.34) | CPB2MEN1MITFKMT2AEPHX1 | |
| SCHEMBL21335133 | 0.89 | CPB2 (0.37) | CPB2KDM1AMEN1MITFKMT2A | |
| SCHEMBL21335222 | 0.89 | CPB2 (0.35) | CPB2KDM1AMEN1MITFKMT2A | |
| SCHEMBL19825890 | 0.88 | CPB2 (0.36) | CPB2KDM1AMEN1MITFKMT2A | |
| SCHEMBL19825813 | 0.88 | CPB2 (0.36) | CPB2KDM1AMEN1MITFKMT2A | |
| SCHEMBL19825855 | 0.86 | TP53 (0.33) | CPB2EPHX1METAP2MMP1FCER2 | |
| SCHEMBL18637667 | 0.86 | TP53 (0.33) | CPB2EPHX1METAP2MMP1FCER2 | |
| SCHEMBL23658150 | 0.85 | CPB2 (0.35) | CPB2MEN1MITFKMT2AMMP1 | |
| SCHEMBL19825887 | 0.85 | CPB2 (0.35) | CPB2MEN1MITFKMT2ACDYL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340026-A1 | COMPOUNDS | NEW PHARMA LICENCE HOLDINGS LTD (MT) | 2023-10-26 | — | — | US | disclosed |
| US-20180030092-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340026-A1 | COMPOUNDS | BCAT1, BCAT2, CCNT1 | CPB2 1430/4885KDM1A 3334/4885MEN1 1609/4885 |
| US-20180030092-A1 | COMPOUNDS | BCAT1, BCAT2, IL4I1 | CPB2 1924/4885KDM1A 3260/4885MEN1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.